WMT

123.92

+0.27%↑

COST

994.01

+0.14%↑

TGT

120.79

+1.16%↑

KR

70.32

-3.79%↓

DG.US

119.12

+1.61%↑

WMT

123.92

+0.27%↑

COST

994.01

+0.14%↑

TGT

120.79

+1.16%↑

KR

70.32

-3.79%↓

DG.US

119.12

+1.61%↑

WMT

123.92

+0.27%↑

COST

994.01

+0.14%↑

TGT

120.79

+1.16%↑

KR

70.32

-3.79%↓

DG.US

119.12

+1.61%↑

WMT

123.92

+0.27%↑

COST

994.01

+0.14%↑

TGT

120.79

+1.16%↑

KR

70.32

-3.79%↓

DG.US

119.12

+1.61%↑

WMT

123.92

+0.27%↑

COST

994.01

+0.14%↑

TGT

120.79

+1.16%↑

KR

70.32

-3.79%↓

DG.US

119.12

+1.61%↑

Search

Afya Ltd (Class A)

Open

SectorConsumer defensive

15 2.25

Overview

Share price change

24h

Current

Min

14.3

Max

14.93

Key metrics

By Trading Economics

Income

-5M

176M

Sales

-1.6M

927M

P/E

Sector Avg

9.503

27.787

Dividend yield

4.41

Profit margin

18.945

EBITDA

-120M

277M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+17.96% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

4.41%

3.82%

Next Earnings

7 maj 2026

Market Stats

By TradingEconomics

Market Cap

81M

1.4B

Previous open

12.75

Previous close

15

News Sentiment

By Acuity

100%

0%

126 / 131 Ranking in Consumer defensive

Technical Score

By Trading Central

Confidence

Bullish Evidence

Afya Ltd (Class A) Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

31 mar 2026, 23:31 UTC

Hot Stocks

Stocks to Watch: Nike, RH, NCino

31 mar 2026, 22:35 UTC

Earnings

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 kwi 2026, 00:00 UTC

Acquisitions, Mergers, Takeovers

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mar 2026, 23:50 UTC

Acquisitions, Mergers, Takeovers

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mar 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mar 2026, 23:33 UTC

Market Talk
Major News Events

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mar 2026, 23:21 UTC

Earnings

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mar 2026, 23:14 UTC

Market Talk
Earnings

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mar 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Loss Widens >000002.SZ

31 mar 2026, 22:36 UTC

Earnings

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mar 2026, 22:36 UTC

Earnings

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mar 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mar 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mar 2026, 21:35 UTC

Earnings

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Earnings

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Earnings

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mar 2026, 21:33 UTC

Acquisitions, Mergers, Takeovers

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mar 2026, 21:33 UTC

Earnings

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mar 2026, 21:32 UTC

Earnings

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mar 2026, 21:28 UTC

Earnings

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mar 2026, 21:26 UTC

Earnings

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mar 2026, 21:25 UTC

Earnings

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mar 2026, 21:24 UTC

Market Talk
Earnings

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mar 2026, 21:22 UTC

Earnings

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mar 2026, 21:22 UTC

Earnings

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mar 2026, 21:21 UTC

Earnings

Nike's Digital Channel Still Too Promotional, CFO Says

31 mar 2026, 21:20 UTC

Earnings

Nike CEO: Converse Remains Important to Portfolio

Peer Comparison

Price change

Afya Ltd (Class A) Forecast

Price Target

By TipRanks

17.96% upside

12 Months Forecast

Average 17.6 USD  17.96%

High 22 USD

Low 16 USD

Based on 5 Wall Street analysts offering 12 month price targets forAfya Ltd (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

0

Buy

4

Hold

1

Sell

Technical Score

By Trading Central

18.968 / 19.56Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Strong Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Afya Ltd (Class A)

Afya Limited operates as a medical education group in Brazil. The company operates through three segments: Undergrad, Continuing Education, and Digital Services. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools. The company provides digital health services, such as subscription-based mobile app and website portal that focuses on assisting health professionals and students with clinical decision-making through tools, such as medical calculators, charts, and updated content, as well as prescriptions, clinical scores, medical procedures and laboratory exams, and others. It offers health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, and biomedicine; and degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering, and pedagogy. In addition, the company provides medical postgraduate specialization programs; printed and digital content; and an online medical education platform and practical medical training services. Further, it offers iClinic, a practice management software; educational health and medical imaging solutions through an interactive platform; Cliquefarma, a free-to-use website that tracks prescription drugs, cosmetics and personal hygiene product prices; Shosp, a clinical management software; RX PRO, a solution that connects physicians with the pharmaceutical industry; and Glic, a free diabetes care and management app solution for physicians and patients. The company was founded in 1999 and is headquartered in Nova Lima, Brazil.
help-icon Live chat